Lung cancers often harbour loss-of-function mutations in SMARCA4. Here, the authors demonstrate a vulnerability of SMARCA4-deficient lung cancers for Aurora kinase A inhibition associated with mitotic defects. This evidence concerns the gene SMARCA4 and lung cancer.